A Pilot Study of Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory Patients with Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS).
CPX-351, Gemtuzumab Ozogamicin
The goal of this clinical research study is to learn if it is safe to give CPX-351 (liposomal cytarabine and daunorubicin) when combined with gemtuzumab ozogamicin to patients with relapsed (the disease has come back) or refractory (the disease has not responded to treatment) acute myeloid leukemia (AML) or patients with high risk myelodysplastic syndrome who have failed previous treatment. The effects of this combination treatment will also be studied.
Disease Group: Malignant neoplasms stated as primary lymphoid haematopoietic
Treatment Agent: CPX-351, Gemtuzumab Ozogamicin
Treatment Location: Only at MD Anderson
Sponsor: Jazz Pharmaceuticals
IRB Review and Approval Date: 11/07/2018
Recruitment Status: Open
Projected Accrual: N/A
Information and next steps
Malignant neoplasms stated as primary lymphoid haematopoietic
For general questions about clinical trials: